$VVOS

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test Transaction Expected to Increase Stockholders’ Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances LITTLETON, Colo., Oc

Vivos Therapeutics (VVOS) agreed to buy 11% of SOD Sciences and 50% of its pseudohypoxia test IP for $12M in Series C Convertible Preferred Stock. The deal is expected to close by October 15, 2026, pending conditions. VVOS aims to strengthen its equity and revenue streams as part of its Nasdaq compliance efforts.

Vivos Therapeutics (VVOS) reported a threefold increase in referrals to its Las Vegas sleep centers, expecting Q4 revenue growth. The company targets $3.6M in annual savings by Q4 2026 and projects $1.5M-$3.0M from EEG initiatives, $3.5M from remote monitoring by Q1 2027, and $2.4M-$5.6M from payer contract renegotiations. Management aims for positive cash flow by late 2026 and profitability in 2027.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously reported, Vivos Therapeutics, Inc. (the “Company”) previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), a Secured Promissory Note with an original issuance

Vivos Therapeutics (VVOS) partners with South Palm Cardiovascular Associates to establish a Sleep & Airway Medicine Center in Florida. Vivos will hold 75% of the new entity, AIM Florida, with plans to start operations in Q1 2027. The center aims to treat 250 patients monthly, generating up to $6M annual revenue with 30%+ margins. SPCVA will expand referrals for sleep disorder-related conditions. VVOS stock is currently at $0.25, up 0.58%.

Vivos Therapeutics (NASDAQ:VVOS) said the U.S. Patent and Trademark Office issued U.S. Patent No. 12,697,190, a continuation of a 2024 patent, to broaden IP protection for its Vivos CARE oral device technology for obstructive sleep apnea. The company says the layered patents are harder for competitors to design around and support its FDA-cleared devices for severe adult and pediatric OSA.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth under Item 5.02 of this Current Report on Form 8-K regarding the Separation, Resignation and Executive Transition Agreement, dated as of July 31, 2026 (the “ Separation Agreement ”), between Vivos Th

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June [_], 2026, between Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the signatur